MCRB250117P500
- 0.04
- 0.000.00%
Seres Therapeutics Newsroom
Optimistic Buy Rating for Seres Therapeutics: Breakthrough Therapy Designation and Financial Stability Boost Confidence
Seres Therapeutics Price Target Maintained With a $10.00/Share by Canaccord Genuity
Seres Therapeutics Is Maintained at Buy by Canaccord Genuity
Promising Developments and Financial Stability Drive Buy Rating for Seres Therapeutics
Seres Therapeutics Analyst Ratings
Chardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target
TD Cowen Maintains Seres Therapeutics(MCRB.US) With Buy Rating
Seres Therapeutics (MCRB) Gets a Buy From TD Cowen
Seres Therapeutics Analyst Ratings
J.P. Morgan Downgrades Seres Therapeutics(MCRB.US) to Sell Rating
Canaccord Genuity Maintains Buy on Seres Therapeutics, Maintains $10 Price Target
Seres Therapeutics Analyst Ratings
Oppenheimer Maintains Seres Therapeutics(MCRB.US) With Hold Rating
Oppenheimer Sticks to Their Hold Rating for Seres Therapeutics (MCRB)
CCORF Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $10
Analysts Offer Insights on Healthcare Companies: Seres Therapeutics (MCRB), BioMarin Pharmaceutical (BMRN) and Exact Sciences (EXAS)
Chardan Capital Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $1.25
Buy Rating Affirmed for Seres Therapeutics' SER-155 Amid Anticipated Positive Impact on Infection and GvHD Rates
TD Cowen Maintains Seres Therapeutics(MCRB.US) With Buy Rating
Oppenheimer Maintains Seres Therapeutics(MCRB.US) With Hold Rating